Table 2

Clinical characteristics of spondyloarthropathy patients included in this study

Patient	Sex	Age	SpA subgroup	Ileal inflammation	Colonic inflammation	Endoscopy	Treatment at biopsy taking
1	M	24	AS	acute	chronic quiescent	normal	none
2	M	29	AS	acute	chronic quiescent	normal	NSAID
3	M	38	AS	acute	none	normal	NSAID
4	F	26	ReA	acute	none	normal	NSAID
5	M	40	ReA	none	acute	normal	NSAID
6	M	41	AS	none	acute	lesions	NA
7	M	26	USpA	chronic active	chronic active	lesions	none
8	F	46	USpA	chronic active	chronic quiescent	normal	NSAID
9	M	12	JSpA	chronic active	chronic quiescent	normal	NSAID
10	F	33	AS	chronic active	chronic quiescent	lesions	NSAID
11	F	29	ReA	chronic active	chronic quiescent	lesions	NSAID
12	F	22	USpA	chronic active	chronic quiescent	lesions	NSAID
13	M	26	AS	chronic active	none	lesions	NSAID/SASP
14	M	23	AS	none	chronic active	lesions	NSAID
15	M	23	USpA	no biopsy	chronic active	lesions	NSAID
16	F	31	AS	no biopsy	chronic active	lesions	NSAID/SASP
17	M	30	JSpA	chronic quiescent	none	lesions	NSAID
18	M	32	AS	chronic quiescent	no biopsy	normal	NSAID/SASP
19	M	40	AS	chronic quiescent	no biopsy	lesions	none

AS: ankylosing spondylitis; JSpA: juvenile spondyloarthropathy; NA: not available; NSAID: non-steroidal anti-inflammatory drugs; ReA: reactive arthritis; SASP: salicylazosulphapyridine; USpA: undifferentiated spondyloarthropathy.